Merck (MRK) Has an Oncology-and-Animal-Health Engine Bigger Than the Keytruda-Patent-Cliff Debate

[ad_1] Merck (MRK) is often reduced to one question: what happens when Keytruda eventually loses exclusivity. That debate is understandable, but the latest quarter shows why it is too narrow to describe the business investors own today. In Q1 2026,…






